NLS Pharmaceutics shares are trading higher after the company announced that the FDA reviewed the full protocol for the NLS-1031 study and the Institutional Review Board approved the Phase 3 clinical trial protocol to evaluate Mazindol ER in patients with narcolepsy type 1.
Portfolio Pulse from Benzinga Newsdesk
NLS Pharmaceutics announced that the FDA has reviewed the full protocol for the NLS-1031 study and the Institutional Review Board has approved the Phase 3 clinical trial protocol to evaluate Mazindol ER in patients. This news has led to a rise in the company's shares.
July 03, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NLS Pharmaceutics shares are trading higher after the company received approval from the FDA for the Phase 3 clinical trial protocol for NLS-1031 study.
The FDA's approval of the Phase 3 clinical trial protocol for the NLS-1031 study is a significant milestone for NLS Pharmaceutics. This approval indicates that the company can proceed with its clinical trials, which could potentially lead to the development of a new drug. This news is likely to boost investor confidence in the company, leading to a rise in the company's share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100